🇺🇸 FDA
Patent

US 10729767

Humanized anti-C1s antibodies and methods of inhibiting C1s cleavage

granted A61KA61K2039/505A61K39/395

Quick answer

US patent 10729767 (Humanized anti-C1s antibodies and methods of inhibiting C1s cleavage) held by Bioverativ USA Inc. expires Mon Jul 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Bioverativ USA Inc.
Grant date
Tue Aug 04 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
32
CPC classes
A61K, A61K2039/505, A61K39/395, A61K39/3955, A61P